Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2091]

Treating acute leukaemias of ambiguous lineage

Dr Lindsey Montefiori - Department of Pathology, St. Jude Children's Research...

Treating acute leukaemias of ambiguous lineage ( Dr Lindsey Montefiori - Department of Pathology, St. Jude Children's Research Hospital, USA )

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the...

Dr Jorge Cortes - Augusta University, Augusta, USA

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation ( Dr Jorge Cortes - Augusta University, Augusta, USA )

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D)...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Real world management of multiple myeloma patients

Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina

Real world management of multiple myeloma patients ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )

Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5...

Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany

Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-year results ( Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany )

Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM...

Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain

Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients ( Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain )

FORTE trial: Impact of minimal residual disease on multiple myeloma patients

Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy

FORTE trial: Impact of minimal residual disease on multiple myeloma patients ( Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy )

Evaluation of MRD negativity in patients with relapsed or refractory multiple...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

$Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )$

Clinical implications of MRD detection in infants with KMT2A-rearranged ALL...

Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands

Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated on the Interfant-06 protocol ( Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands )

Predictive factors for overall survival in chronic myeloid leukaemia patients:...

Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy

Predictive factors for overall survival in chronic myeloid leukaemia patients: an analysis by the Gimema CML Italian study ( Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy )

PARP inhibitors in prostate cancer: A promise delivered

Dr Abhishek Tripathi - Stephenson Cancer Center, Oklahoma City, USA

PARP inhibitors in prostate cancer: A promise delivered ( Dr Abhishek Tripathi - Stephenson Cancer Center, Oklahoma City, USA )

PARP inhibitors for prostate cancer - Nurse's view

Laurie M. Connors - Vanderbilt University School of Nursing, Nashville, USA

PARP inhibitors for prostate cancer - Nurse's view ( Laurie M. Connors - Vanderbilt University School of Nursing, Nashville, USA )

More from ecancer